These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 3084535)

  • 1. Chronic human chorionic gonadotropin administration in normal men: evidence that follicle-stimulating hormone is necessary for the maintenance of quantitatively normal spermatogenesis in man.
    Matsumoto AM; Karpas AE; Bremner WJ
    J Clin Endocrinol Metab; 1986 Jun; 62(6):1184-92. PubMed ID: 3084535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of sperm production by human luteinizing hormone in gonadotropin-suppressed normal men.
    Matsumoto AM; Paulsen CA; Bremner WJ
    J Clin Endocrinol Metab; 1984 Nov; 59(5):882-7. PubMed ID: 6434586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicle-stimulating hormone and human spermatogenesis.
    Bremner WJ; Matsumoto AM; Sussman AM; Paulsen CA
    J Clin Invest; 1981 Oct; 68(4):1044-52. PubMed ID: 6793629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reinitiation of sperm production in gonadotropin-suppressed normal men by administration of follicle-stimulating hormone.
    Matsumoto AM; Karpas AE; Paulsen CA; Bremner WJ
    J Clin Invest; 1983 Sep; 72(3):1005-15. PubMed ID: 6411766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
    Matsumoto AM
    J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of sperm production by human chorionic gonadotropin after prolonged gonadotropin suppression in normal men.
    Matsumoto AM; Bremner WJ
    J Androl; 1985; 6(3):137-43. PubMed ID: 3922931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicle-stimulating hormone is required for quantitatively normal inhibin secretion in men.
    McLachlan RI; Matsumoto AM; Burger HG; de Kretser DM; Bremner WJ
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1305-8. PubMed ID: 3142919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism.
    Schaison G; Young J; Pholsena M; Nahoul K; Couzinet B
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1545-9. PubMed ID: 8263139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
    Wallace EM; Gow SM; Wu FC
    J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins from the inception of therapy in men with isolated hypogonadotropic hypogonadism.
    Liu L; Banks SM; Barnes KM; Sherins RJ
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1140-5. PubMed ID: 3142911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men.
    Matthiesson KL; McLachlan RI; O'Donnell L; Frydenberg M; Robertson DM; Stanton PG; Meachem SJ
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3962-9. PubMed ID: 16895950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine control of human spermatogenesis.
    Matsumoto AM; Bremner WJ
    J Steroid Biochem; 1989 Oct; 33(4B):789-90. PubMed ID: 2513453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone.
    Depenbusch M; von Eckardstein S; Simoni M; Nieschlag E
    Eur J Endocrinol; 2002 Nov; 147(5):617-24. PubMed ID: 12444893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men: effects of long term treatment with GnRH agonist infusion and androgen.
    Bhasin S; Yuan QX; Steiner BS; Swerdloff RS
    J Clin Endocrinol Metab; 1987 Sep; 65(3):568-74. PubMed ID: 3114307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
    Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
    J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Male hypogonadotropic hypogonadism: factors influencing response to human chorionic gonadotropin and human menopausal gonadotropin, including prior exogenous androgens.
    Ley SB; Leonard JM
    J Clin Endocrinol Metab; 1985 Oct; 61(4):746-52. PubMed ID: 3928676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens.
    Bagatell CJ; Matsumoto AM; Christensen RB; Rivier JE; Bremner WJ
    J Clin Endocrinol Metab; 1993 Aug; 77(2):427-32. PubMed ID: 8345047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.